Article
Respiratory System
Xiaoping Wu, Yunju Jeong, Sergio Poli de Frias, Imaani Easthausen, Katherine Hoffman, Clara Oromendia, Shahrad Taheri, Anthony J. Esposito, Luisa Quesada Arias, Ehab A. Ayaub, Rie Maurer, Ritu R. Gill, Hiroto Hatabu, Mizuki Nishino, Michelle L. Frits, Christine K. Iannaccone, Michael E. Weinblatt, Nancy A. Shadick, Paul F. Dellaripa, Augustine M. K. Choi, Edy Y. Kim, Ivan O. Rosas, Fernando J. Martinez, Tracy J. Doyle
Summary: The study identified molecular signatures associated with interstitial lung disease in rheumatoid arthritis, providing potential non-invasive diagnostic tools and future therapeutic targets.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ilyes Benlala, Agnes Albat, Elodie Blanchard, Julie Macey, Chantal Raherison, Thomas Benkert, Patrick Berger, Francois Laurent, Gael Dournes
Summary: This study assessed the feasibility of quantifying T-2 interstitial lung disease signal-intensity volume using a semi-automated method and found that T-2-ISIV was significantly correlated with disease severity in IPF patients and higher in IPF patients compared to controls.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2021)
Review
Cell Biology
Shengnan Yang, Peipei Liu, Yale Jiang, Zai Wang, Huaping Dai, Chen Wang
Summary: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unknown causes, and currently the only medications that can slow down the progression of the disease and improve survival rate are pirfenidone and nintedanib. The use of mesenchymal stem cells (MSCs) provides a new hope for treating interstitial lung disease, but optimal treatment protocols are still lacking.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Roxana-Elena Cirjaliu, Mariana Deacu, Ioana Gherghisan, Angela Stefania Marghescu, Manuela Enciu, Gabriela Izabela Baltatescu, Antonela Anca Nicolau, Doina-Ecaterina Tofolean, Oana Cristina Arghir, Ariadna-Petronela Fildan
Summary: This review provides a comprehensive analysis of the risk factors, clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF). It highlights the similarities and differences between these two diseases by gathering relevant articles published in English up until October 2022 using multiple databases. This review aims to assist clinicians, pathologists, and researchers in making accurate diagnoses and selecting patients for anti-fibrotic therapies and future therapeutic perspectives.
Article
Biochemistry & Molecular Biology
Veronica Pulito-Cueto, Fernanda Genre, Raquel Lopez-Mejias, Victor Manuel Mora-Cuesta, David Iturbe-Fernandez, Virginia Portilla, Maria Sebastian Mora-Gil, Javier Gonzalo Ocejo-Vinyals, Oreste Gualillo, Ricardo Blanco, Alfonso Corrales, Ivan Ferraz-Amaro, Santos Castaneda, Jose Manuel Cifrian Martinez, Belen Atienza-Mateo, Sara Remuzgo-Martinez, Miguel Angel Gonzalez-Gay
Summary: The aim of this study was to investigate the role of endothelin-1 (ET-1) as a biomarker of interstitial lung disease (ILD), and to differentiate between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD). The study included a large cohort of ILD patients and healthy controls, and found that ET-1 levels were increased in IPF and AD-ILD patients compared to controls. However, ET-1 levels could not differentiate between IPF and AD-ILD, and were associated with worse lung function in IPF and RA-ILD patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Respiratory System
Aparna C. Swaminathan, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Luca Paoletti, Eric S. White, Scott M. Palmer, Timothy P. M. Whelan, Daniel F. Dilling
Summary: This study identifies the factors associated with lung transplant or death in patients with idiopathic pulmonary fibrosis (IPF). Age, income, and access to lung transplant centers are found to influence the likelihood of receiving a lung transplant or dying. Interventions are needed to address the socioeconomic disparities in lung transplantation.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2022)
Article
Medicine, General & Internal
Masamichi Komatsu, Hiroshi Yamamoto, Yoshiaki Kitaguchi, Satoshi Kawakami, Mina Matsushita, Takeshi Uehara, Takumi Kinjo, Yosuke Wada, Takashi Ichiyama, Kazuhisa Urushihata, Atsuhito Ushiki, Masanori Yasuo, Masayuki Hanaoka
Summary: Progressive fibrosing interstitial lung disease (PF-ILD) is a type of fibrosing ILD with unclear clinical characteristics and poor prognosis. Patients with PF-ILD require more intensive treatment and have a higher mortality rate, similar to that of patients with idiopathic pulmonary fibrosis.
Review
Biochemistry & Molecular Biology
Sheiphali Gandhi, Roberto Tonelli, Margaret Murray, Anna Valeria Samarelli, Paolo Spagnolo
Summary: Idiopathic pulmonary fibrosis (IPF) is a common and severe disease that primarily affects middle-aged and elderly males. In addition to aging, occupational and environmental exposures, as well as lifestyle factors such as smoking and diet, have been associated with an increased risk of IPF. Trigger factors may also lead to acute exacerbations and poor prognosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Medicine, General & Internal
Tinne Goos, Laurens J. De Sadeleer, Jonas Yserbyt, Geert M. Verleden, Marie Vermant, Stijn E. Verleden, Wim A. Wuyts
Summary: A significant portion of ILD patients may develop a progressive fibrosing phenotype similar to IPF, with shared pathophysiological mechanisms and emerging treatment options showing promise for non-IPF ILDs.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Critical Care Medicine
Christopher S. King, Elizabeth Freiheit, A. Whitney Brown, Oksana A. Shlobin, Shambhu Aryal, Kareem Ahmad, Vikramjit Khangoora, Kevin R. Flaherty, Drew Venuto, Steven D. Nathan
Summary: Based on an analysis of the Pulmonary Fibrosis Foundation Patient Registry, it appears that the use of anticoagulants (particularly warfarin) may be associated with an increased risk of death or transplant in patients with ILD. Further research is needed to determine if warfarin and DOACs have varying safety profiles in patients with ILD.
Article
Medicine, General & Internal
Reoto Takei, Toshiaki Matsuda, Jun Fukihara, Hajime Sasano, Yasuhiko Yamano, Toshiki Yokoyama, Kensuke Kataoka, Tomoki Kimura, Atsushi Suzuki, Taiki Furukawa, Junya Fukuoka, Takeshi Johkoh, Yasuhiro Kondoh
Summary: This study aims to investigate whether health-related quality of life (HRQoL) deteriorates in patients with non-idiopathic pulmonary fibrosis (IPF) fibrotic interstitial lung disease (FILD), and to evaluate the differences in HRQoL changes between those with and without progressive pulmonary fibrosis (PPF). The results showed that both SGRQ and CAT scores were significantly deteriorated in patients with PPF compared to those without PPF. Thus, evaluating HRQoL is necessary when assessing PPF.
FRONTIERS IN MEDICINE
(2023)
Article
Medical Laboratory Technology
Qipan Zhang, Lun Guo, Xuxiang Song, Chengna Lv, Pan Tang, Yan Li, Qunli Ding, Mingcai Li
Summary: The study revealed significantly higher levels of IL-36 alpha and IL-36 gamma in CTD-ILD and IPF patients compared to healthy controls, while IL-36Ra levels did not differ significantly. Increased IL-36 levels were associated with disease severity in IPF patients, with high diagnostic value demonstrated by ROC curve analysis for IL-36 alpha in both IPF and CTD-ILD patients.
CLINICA CHIMICA ACTA
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Haishuang Sun, Xiaoyan Yang, Xuebiao Sun, Xiapei Meng, Han Kang, Rongguo Zhang, Haoyue Zhang, Min Liu, Huaping Dai, Chen Wang
Summary: The elastic registration technique can assess the morphological deterioration of lung shrinkage in idiopathic pulmonary fibrosis (IPF), and the log_jac values are significantly correlated with pulmonary function tests (PFTs).
EUROPEAN RADIOLOGY
(2023)
Article
Medicine, General & Internal
Milena Adina Man, Rodica Ana Ungur, Nicoleta Stefania Motoc, Laura Ancuta Pop, Ioana Berindan-Neagoe, Victoria Maria Ruta
Summary: This study characterized and compared the microbiome in three different interstitial lung diseases: idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, and nondifferential interstitial lung disease. The study found that the microbiome in IPF patients was richer compared to the other two diseases.
Article
Physiology
Jade Jaffar, Laura McMillan, Nick Wilson, Con Panousis, Charles Hardy, Hyun-Jung Cho, Karen Symons, Ian Glaspole, Glen Westall, Mae Wong
Summary: This study found that plasma levels of factor XII (FXII) were not higher in patients with idiopathic pulmonary fibrosis (IPF) compared to healthy donors, but tissue FXII levels were elevated in IPF. FXII can induce IL-6 production and enhance migration of fibroblasts, contributing to chronic inflammation and fibrotic disease progression in IPF.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2022)